8-K: Avanos Medical Reports Mixed Q2 Results, Digestive Health Leads Growth

Avanos Medical, Inc. announced a 1.4% increase in total net sales for the second quarter of 2024, driven by strong performance in Digestive Health, while also reporting a net income of $4.3 million compared to a net loss in the same period last year.

Summary

• Avanos Medical reported a 1.4% increase in net sales from continuing operations for the second quarter of 2024, reaching $171.7 million.
• The company achieved a net income of $4.3 million from continuing operations, a significant improvement from a net loss of $4.3 million in the prior year period.
• Adjusted net income was $15.8 million, up from $11.2 million in the same quarter last year.
• Diluted earnings per share from continuing operations were $0.09, compared to a loss of $0.09 per share last year, while adjusted diluted earnings per share was $0.34, up from $0.24.
• Adjusted EBITDA increased to $26.8 million from $22.9 million year-over-year.
• For the first six months of 2024, net sales totaled $337.8 million, a 2.8% increase compared to the same period last year.
• The company's cash balance at June 30, 2024, was $92.2 million, up from $87.7 million at the end of 2023.
• Avanos anticipates full-year revenue from continuing operations to be between $685 million and $705 million, with adjusted diluted earnings per share between $1.30 and $1.45.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's return to profitability and strong performance in Digestive Health, but there are some concerns about gross margin and the decline in HA product sales. The company's forward guidance is also positive.

Positives

• Avanos achieved a net income of $4.3 million in Q2 2024, a significant improvement from a net loss in the same period last year.
• The Digestive Health segment is experiencing strong growth, driving overall sales increases.
• Selling and general expenses decreased as a percentage of net sales, indicating improved cost management.
• Free cash flow improved significantly, with an inflow of $21.9 million in Q2 2024 compared to an outflow of $6.6 million in Q2 2023.
• The company's cash balance increased to $92.2 million at the end of June 2024.

Negatives

• Gross margin decreased to 55.7% from 57.7% in the prior year period, primarily due to transformation costs and plant separation costs.
• There was reduced demand for hyaluronic acid (HA) products, which partially offset the positive sales growth.
• Net sales from discontinued operations decreased significantly, from $30.4 million to $13.6 million in Q2 2024.
• The Pain Management and Recovery segment experienced a slight decrease in sales, with Surgical pain and recovery down 7.2% in Q2.

Risks

• The company faces risks related to economic conditions that could affect demand for its products.
• Pricing pressures and cost-containment measures could impact the price and demand for Avanos' products.
• Supply chain disruptions, including shortages in drugs used in Surgical Pain and Recovery products, pose a risk.
• Ongoing regional conflicts and changes in foreign exchange markets could affect the company's performance.
• The company's transformation initiative and divestiture transactions carry execution risks.
• Changes in reimbursement levels from third-party payors could impact revenue.
• There is a risk of increased product liability claims and the impact of legal proceedings.

Future Outlook

Avanos anticipates full-year revenue from continuing operations to be between $685 million and $705 million, with adjusted gross margins between 59.5% and 60.5% and adjusted diluted earnings per share between $1.30 and $1.45.

Management Comments

• Joe Woody, Avanos' chief executive officer, stated that they are pleased with the second quarter results and the progress made at the mid-year point.
• Woody noted that Digestive Health continues to lead with high-single digit growth, while Pain Management and Recovery performance is improving.
• Management expects mid-single digit growth for the remainder of the year.

Industry Context

Avanos' performance reflects the broader trends in the medical technology industry, where companies are focusing on specific growth areas while managing costs and navigating supply chain challenges. The growth in Digestive Health aligns with the increasing demand for specialized medical nutrition solutions, while the challenges in Pain Management and Recovery highlight the competitive landscape in that sector.

Comparison to Industry Standards

• Avanos' 1.4% net sales growth is moderate compared to some high-growth medical device companies, but it is a positive sign given the company's ongoing transformation efforts.
• Companies like Medtronic and Stryker, which are larger and more diversified, often report higher growth rates, but Avanos' focus on specific segments like Digestive Health allows for targeted growth.
• The adjusted EBITDA margin of approximately 15.6% (26.8/171.7) is within the range of profitability for medical device companies, but there is room for improvement.
• The company's free cash flow improvement is a positive sign, as many medical device companies are focused on generating strong cash flow to fund growth and acquisitions.
• Compared to smaller, more specialized medical device companies, Avanos' performance is mixed, with strong growth in some areas offset by declines in others.

Stakeholder Impact

• Shareholders will likely view the return to profitability and improved free cash flow positively.
• Employees may be impacted by the ongoing transformation process and restructuring efforts.
• Customers will benefit from the company's focus on delivering clinically superior solutions.
• Suppliers may be affected by changes in the company's supply chain and procurement strategies.
• Creditors will be reassured by the company's improved financial performance and cash position.

Next Steps

• Avanos will continue to execute on its transformation initiative.
• The company will focus on driving growth in its Digestive Health segment.
• Avanos will work to improve performance in the Pain Management and Recovery segment.
• The company will host a conference call to discuss the results.

Key Dates

Keywords

Avanos Medical, Financial Results, Second Quarter, Digestive Health, Pain Management, EBITDA, Net Sales, Earnings Per Share, Medical Technology, Transformation